BU-NOT-SET

CONTACT US
Faster, smaller, smarter: Intelligent manufacturing of mRNA through the power of process analytical technologies
  • Biologics
  • Manufacturing
Man in lab
Webinar
ReciBioPharm: The Economic Case for Continuous Manufacturing
  • Biologics
two people looking at a paper
Insight
The innovation bottleneck: Why drug development is so tough, and how connectivity and predictive analysis can overcome obstacles
  • Drug product
  • Manufacturing
logo recipredict
Insight
What are the key trends shaping drug development in 2025?
  • Industry trends
containers
Insight
ReciBioPharm Is Advancing xRNA Production
  • Biologics
xRNA
Insight
Navigating the complexities of pre-filled syringes for biologics
  • Drug product
  • Manufacturing
syringes
eBook
Unlocking the potential of mRNA with robust lyophilisation strategies
  • Drug product
  • Manufacturing
containers
Insight
Advanced Bio Is Advancing AAV Production
  • Biologics
Recipharm_AdvancedBio_Adeno associated virus
Insight
Advanced is advancing xRNA manufacturing
  • Biologics
Recipharm_AdvancedBio_lab
Insight
Insight
  • Industry trends
Brexit: What’s next for UK pharma?
Insight
  • Drug substance
Navigating approval filings choppy international waters
Insight
  • Drug substance
Regulatory requirements for drug substances
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies